Workflow
CRO概念股
icon
Search documents
CRO概念股震荡上扬,九洲药业涨停
Xin Lang Cai Jing· 2025-09-25 01:58
Group 1 - The CRO concept stocks experienced significant fluctuations, with JiuZhou Pharmaceutical hitting the daily limit up [1] - ProLogis Pharmaceutical rose over 5%, indicating strong market interest [1] - Other companies such as Zhaoyan New Drug, Kangpeng Technology, Aopu Mai, and Haoyuan Pharmaceutical also saw increases in their stock prices [1]
港股异动 | CRO概念股涨幅居前 行业二季度收入利润增速继续环比改善 机构称板块发展趋势向好
智通财经网· 2025-09-01 03:46
Group 1 - CRO concept stocks have shown significant gains, with WuXi AppTec (02359) up 6.3% to HKD 114.7, WuXi Biologics (02269) up 6.02% to HKD 35.2, and others also experiencing notable increases [1] - Dongwu Securities reports that 22 CXO listed companies are expected to see revenue, net profit attributable to parent, and net profit excluding non-recurring gains and losses grow by 14.16%, 64.03%, and 24.82% year-on-year for the first half of 2025, respectively [1] - The second quarter of 2025 is projected to show further improvement in revenue and profit growth rates, with expected increases of 15.15% in revenue and 53.58% in net profit attributable to parent [1] Group 2 - Xiangcai Securities highlights the active performance of the innovative drug industry chain under the backdrop of national encouragement for innovation, despite ongoing pressures from medical insurance cost control [2] - The establishment of a multi-tiered payment system and the rigid demand for medical services are expected to stabilize and rebound the industry [2] - Companies such as WuXi AppTec, Haoyuan Pharmaceutical, and WuXi Biologics are recommended for attention in the ADC CDMO and peptide CDMO sectors [2]
港股异动 | CRO概念股涨幅居前 创新药热潮反哺新药研发需求起量 投融资整体呈现回暖趋势
智通财经网· 2025-08-13 07:52
Group 1 - CRO concept stocks have shown significant gains, with notable increases in share prices for companies such as Viatris Bio (+12.83%), Zhaoyan New Drug (+9.23%), and others [1] - WuXi AppTec has raised its full-year sales forecast after reporting a 141.6% year-on-year increase in TIDES business revenue, reaching RMB 5.03 billion in the first half of the year, driven by high demand in the GLP-1 sector [1] - CICC believes that the valuation center for innovative drug sectors has been adjusted upwards, which will enhance domestic new drug R&D demand and increase financing activity for primary innovative drug projects [1] Group 2 - The U.S. Bureau of Labor Statistics reported stable inflation in July, reducing barriers for potential interest rate cuts by the Federal Reserve in September [2] - Overall investment and financing trends are showing signs of recovery, with prices for preclinical CRO, clinical CRO, and CDMO services stabilizing [2] - The international CDMO business maintains a reasonable pricing structure, with the impact of high pandemic baselines now absorbed [2]
CRO概念股局部拉升,灵康药业涨停
news flash· 2025-06-30 01:51
Group 1 - The CRO concept stocks experienced a partial surge, with Lingkang Pharmaceutical (603669) hitting the daily limit up [1] - Baicheng Pharmaceutical (301096), Kangpeng Technology, Zhaoyan New Drug (603127), and Kailaiying (002821) also saw increases [1]
A股开盘,沪指开跌0.04%,深证成指开跌0.09%,创业板指开跌0.16%,CRO概念股领跌。
news flash· 2025-06-18 01:30
Group 1 - The A-share market opened with the Shanghai Composite Index down by 0.04% [1] - The Shenzhen Component Index opened down by 0.09% [1] - The ChiNext Index opened down by 0.16% [1] - CRO concept stocks led the decline in the market [1]